Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 20, 2019

View Archived Issues

Fibrosis in the lung

New preclinical model of fibrosis

AKS-130 as a novel long-acting insulin for cancer therapy

New small molecule VMY- BC-1 shows promise in vitro for TNBC

Phase I data for HQP-1351 in patients with TKI-resistant CML

Final phase II data for LCL-161 in patients with myelofibrosis

Gamida Cell presents phase I data for cellular therapy using GDA-201

Topline data presented from E.U. phase III study of Wynzora Cream for psoriasis vulgaris

Results from the first patient cohort of INSIGHT-004 phase I study

First patient enrolled in phase III GUARD study of ADX-2191 for prevention of PVR

Embera NeuroTherapeutics receives funding to advance EMB-001 into phase II studies

NexImmune receives IND clearance for phase I/II study of NEXI-002 in multiple myeloma

Spravato nasal spray approved in Europe

New plasma biomarkers found for amyotrophic lateral sclerosis

Scientists report insights into the mechanics, literally, of IPF

Crinetics Pharmaceuticals describes new melanocortin MC2 receptor antagonists

AC Immune discovers microtubule-associated protein tau aggregation inhibitors

New adenosine A2A receptor antagonists identified at Evotec, Ex Scientia

Jiangsu Vcare Pharmatech patents neurotrophic tyrosine kinase receptor inhibitors

Roche describes new Toll-like receptor 7/8/9 antagonists

Imeglimin completes pivotal phase III program for type 2 diabetes in Japan

Bone Therapeutics submits CTA for pivotal study of JTA-004 for knee osteoarthritis

Axovant reports preliminary findings from expanded access treatment with AXO-AAV-GM1

Cullinan Oncology announces phase I/IIa trials of VK-2019 and CLN-081

FDA approves Ervebo for prevention of Ebola virus disease

Popular Stories

Today's news in brief
BioWorld
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
Keros reports beneficial effects of RKER-065 in ALS model
BioWorld Science
Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
News in brief
BioWorld Asia
BioWorld Asia briefs for March 17, 2026
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...